Clinical trials: Left Ventricular Remodeling
Acute Myocardial Infarction
Effects of Cardiac Rehabilitation on High Mobility Group Box-1 Levels After Acute Myocardial Infarction
This purpose of this study is to examine the relationship between HMGB-1 and postinfarction predictors of outcome such as cardiopulmonary and echocardiographic parameters before and after a 6-month exercise-based cardiac…
- Trial name
- NCT00755131
- Testing
- Exercise-based Cardiac Rehabilitation program
- Where
- Italy
- Volunteers
- 75 people
- Sponsor
- Federico II University
Heart Failure
REmodeling the Left Ventricle With Atrial Modulated Pacing
New therapy tested in heart failure with preserved ejection fraction (HFpEF) patients with approved indications for pacing to determine if elevated pacing therapy is tolerated and whether there is a signal for efficacy.
- Trial name
- REVAMP (NCT03210402)
- Testing
- Elevated night pacing on, Elevated night pacing off
- Where
- 10 sites in United States
- Volunteers
- 22 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure, Cardiomyopathies
The Impact of Zinc Supplementation on Left Ventricular Function in Nonischemic Cardiomyopathy
Heart failure affects over 5.3 million Americans and, while other cardiovascular diseases have enjoyed a reduction in mortality rates over the last decade, the mortality from heart failure continues to rise[1].
- Trial name
- NCT00696410
- Testing
- Zinc Acetate
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of Michigan
Diabetes
Impact of Diabetes on Left Ventricular Remodeling
The investigators hypothesize that in patients with diabetes and acute myocardial infarction (MI), Ang II type-1 receptor blockade (AT1RB) attenuates left ventricle (LV) remodeling to a greater extent than angiotensin converting…
- Trial name
- P3 (NCT01052272)
- Testing
- Ramipril, Candesartan cilexetil, Allopurinol
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- University of Alabama at Birmingham
Heart Failure
REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE)
Heart failure is a progressive disease that decreases the pumping action of the heart. This may cause a backup of fluid in the heart and may result in heart beat changes.
- Trial name
- NCT00271154
- Testing
- Cardiac Resynchronization Therapy (CRT) Device or Implantable Cardioverter Defibrillator (ICD) with CRT
- Where
- 65 sites in United States, Austria and 13 more
- Volunteers
- 684 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Myocardial Infarction
Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)
The core and extension studies assessed the safety and efficacy of aliskiren when added to optimized standard therapy in patients that have had a high risk acute myocardial infarction (heart attack).
- Trial name
- NCT00414609
- Testing
- Aliskiren
- Where
- 23 sites in United States, Argentina and 21 more
- Volunteers
- 820 people
- Sponsor
- Novartis
Heart Failure
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
This study was to determine early and more chronic changes in concentrations of biomarkers related to mechanisms of action (MOA) and effects of sacubitril/valsartan therapy over a period of 12 months, and correlated these…
- Trial name
- PROVE-HF (NCT02887183)
- Testing
- LCZ696 (sacubitril/valsartan)
- Where
- 77 sites in United States
- Volunteers
- 794 people
- Sponsor
- Novartis Pharmaceuticals
Acute ST Elevation Myocardial Infarction
REVEAL: Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction
The purpose of this study is to evaluate whether erythropoietin can help limit the damage to the heart in patients with acute heart attacks.
- Trial name
- NCT00378352
- Testing
- Epoetin alfa
- Where
- 16 sites in United States
- Volunteers
- 223 people
- Sponsor
- National Institute on Aging (NIA)
Heart Failure, Dilated Cardiomyopathy
Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure
The purpose of this study is to evaluate whether patients with chronic heart failure not due to coronary artery disease who require use of a left ventricular assist device (LVAD) for refractory heart failure can recover…
- Trial name
- HARPS (NCT00585546)
- Testing
- clenbuterol
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- Francis D. Pagani
Aortic Stenosis, LV Remodeling, Hypertrophy
Aortic Stenosis and PhosphodiEsterase Type 5 iNhibition (ASPEN): A Pilot Study
Currently, aortic stenosis (AS) is considered a "surgical disease" with no medical therapy available to improve any clinical outcomes, including symptoms, time to surgery, or long-term survival.
- Trial name
- ASPEN (NCT01275339)
- Testing
- Tadalafil
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Washington University School of Medicine
Heart Failure
The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI
Prior to reperfusion therapy, the major therapeutic breakthrough in myocardial infarction was the demonstration that ACE inhibitors or ARBs, given to prevent adverse "remodelling" (progressive dilatation and decline in systolic…
- Trial name
- RECOVER-LV (NCT03552575)
- Testing
- sacubitril/valsartan, Valsartan
- Where
- 2 sites in United Kingdom
- Volunteers
- 93 people
- Sponsor
- NHS Greater Glasgow and Clyde
Hypertension, Left Ventricle Hypertrophy
ALiskiren or Losartan Effects on bioMARKers of Myocardial Remodeling
The purpose of this study is to assess efficacy of aliskiren for reducing circulating levels of biomarkers of left ventricular (LV) remodeling associated with LV hypertrophy (LVH) in hypertensive patients.
- Trial name
- ALLMARK (NCT01176032)
- Testing
- Aliskiren, Losartan, Amlodipine
- Where
- 25 sites in Spain
- Volunteers
- 74 people
- Sponsor
- Novartis Pharmaceuticals
Aortic Valve Stenosis
Hemodynamic Comparison of Tissue Aortic Valves
The purpose of this study is to: 1. Assess for hemodynamic differences at rest and with exercise between three clinically available tissue aortic valves. 2.
- Trial name
- NCT01635244
- Testing
- Aortic valve replacement
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Michigan